New Tuberculosis Vaccine Candidate Developed: Improved Delivery Of Antigens By Current Vaccine BCG (Bacille Calmette-Gurin)

Scientists at the Max Planck Institute for Infection Biology, Berlin and at the University Clinics of Ulm have developed a putative vaccine candidate against Mycobacterium tuberculosis, the causative agent of tuberculosis. Their data have been published in the Proceedings of the National Academy of Sciences U.S.A. on April 28, 1998.

Although tuberculosis belongs to the "old" diseases, it still remains a significant global health problem. Tuberculosis is responsible for 3 million deaths annually - more than at any time-point before and more than any other infectious agent. Moreover, it has been estimated that half a billion people will suffer from tuberculosis by the year 2050. Already in 1927, a vaccine was developed which was termed bacille Calmette-Gurin (BCG) to honour the scientists who attenuated Mycobacterium bovis by more than 230 passages on bile glycerol agar. In many countries the only measure for tuberculosis control has been vaccination with BCG. General agreement exists that BCG can protect or at least ameliorate severe forms of tuberculosis in children. Yet, it seems to be of low or no protective value in adults.

M. tuberculosis belongs to the group of intracellular bacteria that replicate within the phagosomal vacuoles of resting macrophages and protection against tuberculosis depends on T cell-mediated immunity. Major histocompatiblity complex (MHC) class II-restricted CD4 T helper cells and MHC class I-restricted cytotoxic CD8 T cells are stimulated during M.tuberculosis infection, but the current BCG vaccine fails to prime CD8 T cells for tuberculosis prevention.

Over the last few years, Juergen Hess and Stefan H.E. Kaufmann from the Max Planck Institute for Infection Biology in Berlin and the University Clinics of Ulm developed recombinant ( r )- BCG strains which secrete pore-f

Contact: Juergen Hess

Page: 1 2

Related biology news :

1. Scientists Identify Molecular Target For Tuberculosis Drug Treatment
2. Scientists Unlock Mystery Behind Proteins That Keep Tuberculosis Bacteria Alive; Finding Leads To Research Into New Drug Treatments
3. Hope Clinic of Emory Vaccine Center receives CDC contract
4. Vaccines against foodborne disease on horizon
5. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
6. Vaccine technique shows potential against common form of lung cancer
7. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
8. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
9. Vaccine prevents stroke in rats
10. Vaccine puts blood-sucking ticks off their food
11. Vaccine protects against fatal West Nile complication

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: